Sign in to enjoy up to 20% OFF or Register
  •  
[email protected]
Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others
+1 800-931-7508 [email protected]
Sign in to enjoy up to 20% OFF

[CAS NO. 56180-94-0]  Acarbose

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [56180-94-0]

Catalog
HY-B0089
Brand
MCE
CAS
56180-94-0

DESCRIPTION [56180-94-0]

Overview

MDLMFCD00869592
Molecular Weight645.60
Molecular FormulaC25H43NO18
SMILESOC[C@H]([C@]1(O[C@@H]2[C@H](O)[C@@H](O)[C@@H]([C@H](O2)C)N[C@]3(C=C(CO)[C@H]([C@@H]([C@H]3O)O)O)[H])[H])O[C@@H]([C@@H]([C@H]1O)O)O[C@@]([H])([C@@H]([C@H](C=O)O)O)[C@@H](CO)O

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE


Summary

Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor ( IC 50 =11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin [1] [2] [3] .


In Vitro

Acarbose (1, 2, and 3 μM) dose- and time-dependently inhibits TNF-α-induced VSMC proliferation and migration. Acarbose (1, 2, and 3 μM) dose-dependently decreases β-galactosidase, Ras expression and increased p-AMPK expression in TNF-α pre-treated A7r5 cells [5] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

Acarbose (300 mg/60 kg body weight) decreases the fasting blood glucose, and regulates the glucose tolerance of DM rats without body weight loss. Acarbose significantly suppresses serum IL6 and TNF-α in DM rats [4] .
Acarbose (2.5 and 5.0 mg/kg) significantly and dose-dependently decreases the intensity of neointimal IL-6, TNF-α, and iNOS staining, and significantly increases the intensity of neointimal p-AMPK staining. Acarbose (2.5 and 5.0 mg/kg) significantly and dose-dependently decreases neointimal Ras and β-galactosidase expression in HCD-fed rabbits without body weight loss [5] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT01514838 Astellas Pharma Inc
Type II Diabetes Mellitus
April 23, 2012 Phase 3
NCT02043886 University of British Columbia|Canadian Diabetes Association
Type 2 Diabetes|Postprandial Hypotension
June 2007 Phase 2
NCT00846521 Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pediatric Obesity|Insulin Resistance|Impaired Glucose Tolerance|Cardiovascular Disease
September 2006 Phase 4

Appearance

Solid


Source

Actinoplanes sp


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

H 2 O : 100 mg/mL ( 154.89 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.5489 mL 7.7447 mL 15.4895 mL
5 mM 0.3098 mL 1.5489 mL 3.0979 mL
10 mM 0.1549 mL 0.7745 mL 1.5489 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: PBS

    Solubility: 100 mg/mL (154.89 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

* All of the co-solvents are available by MCE.


Synonyms

D-Glucose, O-4,6-dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-α-D-glucopyranosyl-(1→4)-O-α-D-glucopyranosyl-(1→4)-
D-Glucose, O-4,6-dideoxy-4-[[4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-α-D-glucopyranosyl-(1→4)-O-α-D-glucopyranosyl-(1→4)-, [1S-(1α,4α,5β,6α)]-
O-4,6-Dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-α-D-glucopyranosyl-(1→4)-O-α-D-glucopyranosyl-(1→4)-D-glucose
BAY-g 5421
Acarbose
Glucobay
Ascarbose
Precose
Prandase
Arcabose
(2R,3R,4R,5R)-4-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-Dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-enyl]amino]tetrahydro-2H-pyran-2-yl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy]-2,3,5,6-tetrahydroxyhexanal
(2R,3R,4R,5R)-4-(((2R,3R,4R,5S,6R)-5-(((2R,3R,4S,5S,6R)-3,4-Dihydroxy-6-methyl-5-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-enyl)amino)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2,3,5,6-tetrahydroxyhexanal
Acarviostatin I01

Information
Shipping
Privacy notice
Terms of Service
About us
Contact us
Customer services
Search
Custom Synthesis
My account
My account
Orders
Addresses
Shopping cart
Pay
Powered by Arctom Copyright © 2025 Arctom. All rights reserved.